<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340661</url>
  </required_header>
  <id_info>
    <org_study_id>TGD-01</org_study_id>
    <nct_id>NCT04340661</nct_id>
  </id_info>
  <brief_title>Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients</brief_title>
  <official_title>Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targeting Gut Disease S.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targeting Gut Disease S.R.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this double blind placebo-controlled study is to evaluate the effect of
      BIOintestil on fecal microbiota, inflammatory chemokines and symptoms in patients affected by
      Irritable Bowel Syndrome (IBS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BIOintestil is a dietary supplement based on Palmrose oil (Cymbopogon martinii) and ginger
      ryzoma powder. Palmrose oil effects were already established in animal model of colitis and
      in a pilot study on patients with IBS. In this study, 108 patients will be randomized to
      receive BIOintestil or placebo in a 1:1 ratio, for four weeks. Fecal and blood samples will
      be collected at each visit for microbiota and chemokine analysis, patients syntoms will be
      evaluated by administration of the validated IBS-VAS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fecal Microbiota composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>relative abundance of bacteroidetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in circulating cytokines and chemokines</measure>
    <time_frame>4 weeks</time_frame>
    <description>IL-1β, IL-4, IL-6, IL-10,IL-17A,IL-17F, IL-21, IL-22, IL-23, IL-25, IL31, IL-33, IFN-γ, MIP-1b , MCP-1 cytokines and chemokines will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome-Visual Analogue Scale (IBS-VAS) score improvement</measure>
    <time_frame>4 weeks</time_frame>
    <description>Irritable Bowel Syndrome-Visual Analogue Scale is designed to measure the treatment response of symptoms and well-being in patients suffering from IBS. It is composed by 4 items:
1) abdominal pain, 2) Abnominal bloating, 3) Satisfaction of the intestinal habits 4) influence on daily life. The patients are asked to record in the VAS-IBS the overall severity of each of the 4 items on a 100-mm-long horizontal line (&quot;very severe discomfort 0&quot; to &quot;no discomfort at all 100&quot;).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Bionocol arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BIOintestil</intervention_name>
    <description>Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)</description>
    <arm_group_label>Bionocol arm</arm_group_label>
    <other_name>BIONOCOL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Cornstarch</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willing of sign written informed consent;

          -  participants affected with Irritable bowel syndrome (IBS) who satisfy Rome III
             criterias for diagnosis

          -  body weight between 48 and 104 kg, with a BMI less than 27

          -  age between 18 and 65 years old

        Exclusion Criteria:

          -  participants that have not taken following medications within 30 days before
             randomization: steroidal anti-inflammatory drugs, antibiotics or supplemntes or
             functional foods that may contain probiotics or prebiotics

          -  women who suspect to be/are pregnant or in lactacy

          -  participants with Inflammatory bowel disease disgnosis or celiac disease or severe
             systemic disease

          -  participants who are intolerant to lactose or with food allergies confirmed

          -  particpiants with confirmed or suspected hypersensibility to one or more of Bionocol®
             components

          -  participants with severe concomitants disease that, by investigator's opinion,
             interfere with study partecipation

          -  participants under anticoagulant therapy or with coagulation disease

          -  participants with renal and hepatic failure

          -  participants who have taken any investigational drug within 2 month the randomization
             visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Rizzello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O.U Policlinico S.Orsola-Malpighi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Chiara Valerii, PhD</last_name>
    <phone>+393284258960</phone>
    <email>chiaravalerri@hotmail.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enzo Spisni, PhD</last_name>
    <email>enzo.spisni@unibo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O.U Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Rizzello, MD</last_name>
      <email>fernando.rizzello@unibo.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Chiara Valerii, PhD</last_name>
      <email>chiaravalerii@hotmail.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiota</keyword>
  <keyword>immune system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

